Systematic Review And Network Meta-Analysis Of All Agents For Stroke Prevention In Patients With Atrial Fibrillation

Abstract

A105overall group (33% vs. 20%; p< 0.0001) and versus the atorvastatin group (34% vs. 24%; p < 0.0001). ConClusions: Propensity score-matched analysis of high-risk patients initiating statins indicated that rosuvastatin was significantly more likely to reduce LDL-C compared with all other statins grouped together and compared with atorvastatin alone in this real world patient population.